3rd Quarter - Report

ASSOCIATION FOR ACCESSIBLE MEDICINES for ASSOCIATION FOR ACCESSIBLE MEDICINES

Firm
Client
Income
—
Expenses
$940,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

6 issue areas, each in the filer's own words, with who lobbied on it and where.

Taxation/Internal Revenue Code TAX

User Fee Programs.

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
DAVID R. GAUGH —
KARIN HESSLER —
ERIK C KOMENDANT —
KRISTIN MURPHY —
JOSEPH STEWART —

Contacted: Federal Trade Commission (FTC); Food & Drug Administration (FDA); Office of Management & Budget (OMB); SENATE; State, Dept of (DOS); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); Natl Economic Council (NEC); Congressional Budget Office (CBO); Centers For Medicare and Medicaid Services (CMS)

Trade (domestic/foreign) TRD

General Trade Issues. Trans-Pacific Partnership (TPP). Biologic Exclusivity. Pharmaceutical Exclusivity. H.R.3379: Price Relief, Innovation, and Competition for Essential Drugs Act. United States-Mexico-Canada Agreement (USMCA). North American Free Trade Agreement (NAFTA). U.S.-UK Trade Agreement. U.S.-Japan Trade Discussions. U.S.-India Trade Discussions. U.S.-European Trade Negotiations. China Tariffs. Secretary Azar Importation Plan.

Contacted: Commerce, Dept of (DOC); Health & Human Services, Dept of (HHS); State, Dept of (DOS); Centers For Medicare and Medicaid Services (CMS); Office of Management & Budget (OMB); Congressional Budget Office (CBO); HOUSE OF REPRESENTATIVES; SENATE; U.S. Trade Representative (USTR); Food & Drug Administration (FDA); Natl Economic Council (NEC); Federal Trade Commission (FTC)

Bills named: H.R. 3379 (116th)

Copyright/Patent/Trademark CPT

Inter Partes Review (IPR) Process. H.R.990/S.344: Hatch-Waxman Integrity Act of 2019. Patent Settlements. Patent Abuse. Patent Obviousness. BPCIA Patent Dance. H.R.3666: STRONGER Patents Act of 2019. Section 101 of the Patent Act. New Chemical Entity Exclusivity (NCE). REMEDY Act (Bill number not yet assigned). S.440: Preserving Access to Cost Effective Drugs (PACED) Act. H.R.2375: Preserve Access to Affordable Generics and Biosimilars Act. S.1416: Affordable Prescriptions for Patients Act of 2019. S.1617: Second Look at Drug Patents Act of 2019. H.R.3199: Terminating the Extension of Rights Misappropriated Act of 2019. Remedy of S.1209: Reforming Evergreening and Manipulation that Extends Drug Years Act.

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
JEFFREY FRANCER —
KARIN HESSLER —
ERIK C KOMENDANT —
KRISTIN MURPHY —
CHRISTINE SIMMON —
JOSEPH STEWART —

Contacted: State, Dept of (DOS); Natl Economic Council (NEC); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Office of Management & Budget (OMB); SENATE; Commerce, Dept of (DOC); Federal Trade Commission (FTC); Congressional Budget Office (CBO); Food & Drug Administration (FDA)

Bills named: H.R. 2375 (116th), S. 1209 (116th), H.R. 3199 (116th), S. 344 (116th), S. 1617 (116th), H.R. 990 (116th), S. 1416 (116th), S. 440 (116th), H.R. 3666 (116th)

Medicare/Medicaid MMM

Medicare Part D Program and Generic Drugs. Medicare Reimbursement for Biosimilars. Medicaid Rebate Penalty. Medicare Part D Low Income Subsidy (LIS) Program. Medicare Part D Coverage Gap Discount Program. H.R.448/S.99: Medicare Drug Price Negotiation Act. H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019. S.62: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019. H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019. S.1895: Lower Health Care Costs Act.

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
CRAIG BURTON —
KARIN HESSLER —
ERIK C KOMENDANT —
KRISTIN MURPHY —
CHRISTINE SIMMON —
JOSEPH STEWART —

Contacted: Food & Drug Administration (FDA); Health & Human Services, Dept of (HHS); State, Dept of (DOS); U.S. Trade Representative (USTR); Commerce, Dept of (DOC); Natl Economic Council (NEC); SENATE; Congressional Budget Office (CBO); Centers For Medicare and Medicaid Services (CMS); Federal Trade Commission (FTC); Office of Management & Budget (OMB); HOUSE OF REPRESENTATIVES

Bills named: S. 1895 (116th), S. 99 (116th), H.R. 275 (116th), S. 377 (116th), S. 62 (116th), H.R. 448 (116th), H.R. 1046 (116th)

Budget/Appropriations BUD

FDA Funding. Public Law 115-123: Bipartisan Budget Act of 2018. Public Law 115-141: Consolidated Appropriations Act of 2018.

LobbyistCovered position, as disclosed
CHRISTOPHER BOWLIN —
CRAIG BURTON —
JEFFREY FRANCER —
DAVID R. GAUGH —
KARIN HESSLER —
ERIK C KOMENDANT —
KRISTIN MURPHY —

Contacted: Office of Management & Budget (OMB); Commerce, Dept of (DOC); Food & Drug Administration (FDA); Natl Economic Council (NEC); SENATE; HOUSE OF REPRESENTATIVES; U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Health & Human Services, Dept of (HHS); Congressional Budget Office (CBO); Federal Trade Commission (FTC); State, Dept of (DOS)

Pharmacy PHA

Implementation of Food and Drug Administration Reauthorization Act (FDARA). Generic Drug User Fee Amendments (GDUFA). Biosimilar User Fee Act (BsUFA). Labeling of Generic Drugs and Biosimilars. Country of Manufacture Labeling. Drug Compounding. Drug Shortages. Product Hopping. H.R.4398: Affordable Prescriptions for Patients Through Promoting Competition Act of 2019. Biosimilars Naming. Biosimilars Insulin. Pass Through Payments for Biosimilars. S.1140: Protecting Access to Biosimilars Act of 2019. H.R.4455: BIOSIM Act. H.R.4597: Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019. H.R.4629: Star Rating for Biosimilars Act. Prescription Drug Costs. American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs. Proposed Anti-Kickback Statute (AKS) Rebates. FDA Citizen Petitions. Suitability Petitions. S.660: Efficiency and Transparency in Petitions Act. H.R.2387: STOP GAMES Act of 2019. H.R.985: FAST Generics Act of 2019. H.R.1506: FAIR Generics Act. H.R.2455/S.1169: Ensuring Timely Access to Generics Act of 2019. H.R.1503: Orange Book Transparency Act of 2019. H.R.1520: Purple Book Continuity Act of 2019. Drug Pricing. S.64: Preserve Access to Affordable Generics and Biosimilars Act. S.1416: Affordable Prescriptions for Patients Act of 2019. H.R.2374/S.1224: Stop STALLING Act. H.R.2376: Prescription Pricing for the People Act of 2019. H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019. H.R.938: Bringing Low-Cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019. H.R.465/S.102: Prescription Drug Price Relief Act of 2019. H.R.1093/S.378: Stop Price Gouging Act. H.R.3: Lower Drug Costs Now Act of 2019. S.474: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019. S.440: Preserving Access to Cost Effective Drugs (PACED) Act. S.1895: Lower Health Care Costs Act. H.R.965/S.340: CREATES Act of 2019. Public Law 115-123: Bipartisan Budget Act of 2018. Risk Evaluation and Mitigation Strategies (REMS). Pharmaceutical Exclusivity. 30-Month Stays. Orphan Drug Exclusivity. Biologic Exclusivity. H.R.3379: Price Relief, Innovation, and Competition for Essential Drugs (PRICED) Act. S.659: Biologic Patent Transparency Act. Biologics Price Competition and Innovation Act (BPCIA). Public Law 115-52: FDA Reauthorization Act of 2017.

Contacted: Federal Trade Commission (FTC); Office of Management & Budget (OMB); Natl Economic Council (NEC); State, Dept of (DOS); U.S. Trade Representative (USTR); Centers For Medicare and Medicaid Services (CMS); Commerce, Dept of (DOC); Food & Drug Administration (FDA); HOUSE OF REPRESENTATIVES; SENATE; Congressional Budget Office (CBO); Health & Human Services, Dept of (HHS)

Bills named: H.R. 3 (116th), H.R. 1503 (116th), H.R. 2455 (116th), H.R. 4597 (116th), H.R. 2376 (116th), S. 1895 (116th), S. 474 (116th), H.R. 4629 (116th), H.R. 4398 (116th), S. 1140 (116th), S. 340 (116th), H.R. 1520 (116th), H.R. 938 (116th), H.R. 1093 (116th), S. 659 (116th), H.R. 1506 (116th), H.R. 3379 (116th), S. 102 (116th), S. 1416 (116th), S. 1169 (116th), S. 660 (116th), S. 64 (116th), S. 1224 (116th), S. 440 (116th), H.R. 1499 (116th), H.R. 985 (116th), H.R. 465 (116th), S. 378 (116th), H.R. 2374 (116th), H.R. 965 (116th), H.R. 4455 (116th), H.R. 2387 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.